WASHINGTON — A federal proposal to impose new restrictions on a key addiction-treatment medicine has prompted an uproar in sure segments of the medical group. However well being secretary Xavier Becerra appears to be on board.
The brand new Drug Enforcement Administration proposal would require that sufferers obtain an in-person examination earlier than acquiring refills of buprenorphine, a key drug used to deal with opioid use dysfunction. When a public emergency was declared in response to Covid-19, sufferers had been allowed to acquire buprenorphine by way of telemedicine or by way of an in-person go to.
Within the wake of the DEA’s proposal, main dependancy medical doctors have warned that limiting entry to the drug might make the opioid disaster even worse. Becerra, nevertheless, mentioned the brand new proposal strikes an applicable stability between security and entry.
commercial
“We’ve been capable of have a very good partnership with DEA to get to a spot the place they really feel like they’re nonetheless going to be defending the general public from the unfold of medication, and we really feel we’re going to have the ability to defend those that try to get the medicine they may want,” Becerra mentioned on Tuesday, talking at a STAT occasion.
Whereas the brand new proposal would nonetheless permit medical doctors to prescribe buprenorphine by way of telemedicine, it could require new sufferers to point out up for an in-person examination inside 30 days in the event that they need to keep on the drug. Present sufferers who had been initiated by way of telemedicine would have a 180-day grace interval earlier than they, too, are topic to the requirement.
commercial
The proposal has garnered intense pushback from the dependancy medication group and even Democratic members of Congress. With over 80,000 People dying every year from opioid overdoses, they warn, any new limitation on dependancy remedy entry might have dire penalties.
Detractors embody the American Society of Dependancy Drugs, Sen. Ed Markey (D-Mass.), and Rep. Paul Tonko (D-N.Y.).
“At a time when 200 folks daily are dying due to opioid overdose, we can not roll again entry to efficient, evidence-based drugs,” Markey instructed STAT in an announcement final week.
In an announcement accompanying the proposal, Anne Milgram, the DEA administrator, mentioned the company was dedicated to “making certain the protection of sufferers,” including that the DEA is “dedicated to the growth of telemedicine with guardrails that stop on-line overprescribing of managed drugs that may trigger hurt.”
Whereas buprenorphine is itself an opioid, it's broadly seen as protected — each basically and particularly compared to the medicine that folks in search of dependancy remedy may in any other case be utilizing, like heroin or fentanyl.
Latest research have proven that the dramatic enhance in buprenorphine entry for the reason that onset of the Covid-19 pandemic didn't end in the next share of opioid overdoses involving buprenorphine. Roughly 2% of opioid overdoses concerned buprenorphine, in line with latest knowledge, and just about all overdoses that concerned buprenorphine additionally concerned different medicine. Total, fewer than 1 in 600 opioid overdoses is attributable to buprenorphine alone.
Becerra, notably, took care to level out that the DEA proposal is “open for public remark” — in different phrases, that the brand new regulation might nonetheless change earlier than it's finalized.
He additionally hinted on the long-simmering pressure between DEA, a regulation enforcement company, and the quite a few public well being businesses that concentrate on drug use and dependancy remedy, together with HHS.
“DEA’s mandate may be very completely different from ours,” Becerra mentioned. “They've to fret about defending the general public from the unfold of medication. I need to maintain folks alive. I would like folks to get off of these medicine. I need to assist them. I don’t need there to be stigma.”
STAT’s protection of persistent well being points is supported by a grant from Bloomberg Philanthropies. Our monetary supporters are usually not concerned in any selections about our journalism.